SynAct Pharma AB Cash Flow Conversion Efficiency
SynAct Pharma AB cash flow conversion efficiency. Based on the latest financial reports, SynAct Pharma AB (SYNACT) has a cash flow conversion efficiency ratio of -0.170x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-32.95 Million ≈ $-3.55 Million USD) by net assets (Skr193.75 Million ≈ $20.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SynAct Pharma AB (2016–2025)
Cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2025. This chart illustrates how SynAct Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SynAct Pharma AB stock quote for real-time trading data and today's change.
SynAct Pharma AB Cash Flow Conversion Ratio Explained
SynAct Pharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SynAct Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SynAct Pharma AB ranked by their cash flow conversion efficiency. Also see SYNACT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elentec Co. Ltd
KQ:054210
|
0.072x |
|
Zeotech Ltd
AU:ZEO
|
-0.080x |
|
DAEYANG ELECTRIC.Co.Ltd
KQ:108380
|
0.047x |
|
Parsan Makina Parcalari Sanayi AS
IS:PARSN
|
0.002x |
|
Chyang Sheng Dyeing & Finishing Co Ltd
TW:1463
|
0.003x |
|
Kandi Technologies Group Inc
NASDAQ:KNDI
|
-0.359x |
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
|
Nasmedia Co. Ltd
KQ:089600
|
-0.051x |
Annual Cash Flow Conversion Efficiency for SynAct Pharma AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2025. Review SynAct Pharma AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr170.29 Million ≈ $18.33 Million |
Skr-97.33 Million ≈ $-10.47 Million |
-0.572x | -37.23% |
| 2024-12-31 | Skr214.17 Million ≈ $23.05 Million |
Skr-89.20 Million ≈ $-9.60 Million |
-0.416x | +26.75% |
| 2023-12-31 | Skr176.19 Million ≈ $18.96 Million |
Skr-100.18 Million ≈ $-10.78 Million |
-0.569x | +38.81% |
| 2022-12-31 | Skr126.52 Million ≈ $13.62 Million |
Skr-117.56 Million ≈ $-12.65 Million |
-0.929x | +70.17% |
| 2021-12-31 | Skr20.87 Million ≈ $2.25 Million |
Skr-65.00 Million ≈ $-6.99 Million |
-3.115x | -48.68% |
| 2020-12-31 | Skr15.87 Million ≈ $1.71 Million |
Skr-33.24 Million ≈ $-3.58 Million |
-2.095x | -75.44% |
| 2019-12-31 | Skr13.50 Million ≈ $1.45 Million |
Skr-16.12 Million ≈ $-1.74 Million |
-1.194x | +49.15% |
| 2018-12-31 | Skr10.31 Million ≈ $1.11 Million |
Skr-24.21 Million ≈ $-2.61 Million |
-2.348x | -76.25% |
| 2017-12-31 | Skr12.91 Million ≈ $1.39 Million |
Skr-17.20 Million ≈ $-1.85 Million |
-1.332x | -144.84% |
| 2016-12-31 | Skr27.08 Million ≈ $2.91 Million |
Skr-14.73 Million ≈ $-1.59 Million |
-0.544x | -- |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and id… Read more